KLRS
Kalaris Therapeutics, Inc.8.66
+0.16+1.88%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
161.96MP/E (TTM)
-Basic EPS (TTM)
-38.05Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Kalaris narrowed Q3 operating losses to $12.7M from $37.8M y/y, as R&D expenses dropped 75% sans last year's $32M royalty obligation hit, while clinical costs climbed on TH103 Phase 1a/1b/2 nAMD trials. Net loss improved to $11.9M ($0.64/share) from $38.1M ($28.16/share, derived), reconciling to 18.7M diluted shares. Merger closed March 18, 2025, injecting $102.1M cash; quarter-end liquidity hit $77.0M in cash/short-term investments, funding ops into 2027. Cash burn steepened to $31.3M YTD from $12.8M y/y. Cash is king.
8-K
Q3 loss narrows, cash strong
Kalaris Therapeutics reported Q3 2025 net loss of $11.9M, down from $38.1M last year, with R&D expenses dropping to $9.1M after skipping a $32M royalty hit. Cash hit $77.0M, funding ops into 2027 post-AlloVir merger. Phase 1a TH103 data due year-end; Phase 1b/2 enrolling. Hired CFO, CDMO, HQ open. Momentum builds.
8-K
CFO appointment announced
Kalaris Therapeutics appointed Matthew Gall as CFO and Treasurer, effective November 3, 2025, bringing experience from iTeos and Sarepta. He gets $485,000 base salary, 40% target bonus, and options for 235,000 shares vesting over four years. Brett Hagan steps down as principal financial officer but stays as chief accounting officer. New finance lead locked in.
8-K
Kalaris Q2 loss widens on trial ramp-up
Kalaris Therapeutics reported Q2 2025 net loss of $11.4 million, up from $5.7 million year-over-year, driven by $8.4 million in R&D expenses as the Phase 1 trial for TH103 in nAMD patients advances. Cash reserves hit $88.4 million post-merger with AlloVir, funding operations into Q4 2026. Initial safety and efficacy data expected Q4 2025. Clinical delays pose risks.
10-Q
Q2 FY2025 results
Kalaris Therapeutics posted a $11.4M net loss for Q2 FY2025 ended June 30, 2025, up from $5.7M a year earlier, driven by $12.3M in operating expenses that swelled 193% y/y amid ramped-up R&D for its lead anti-VEGF candidate TH103. R&D costs jumped 163% y/y to $8.4M, fueled by Phase 1 trial initiation and manufacturing scale-up, while G&A expenses more than tripled to $3.8M on merger-related professional fees and public company costs. The Merger with AlloVir closed in March 2025 for stock consideration, injecting $102.1M in cash and recognizing no goodwill or intangibles beyond existing assets. Cash and equivalents stood at $88.4M at quarter-end, with no debt outstanding and free cash flow not disclosed in the 10-Q. Yet regulatory hurdles loom large for TH103's path to approval.
ACRS
Aclaris Therapeutics, Inc.
3.21+0.04
IMA
ImageneBio, Inc.
6.25+0.08
KALA
KALA BIO, Inc.
0.56-0.05
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
KPRX
Kiora Pharmaceuticals, Inc.
2.04-0.02
LENZ
LENZ Therapeutics, Inc.
16.70-0.38
NBY
NovaBay Pharmaceuticals, Inc.
3.16+0.45
OCS
Oculis Holding AG
19.84-0.63
OTLK
Outlook Therapeutics, Inc.
2.47+0.30
TRML
Tourmaline Bio, Inc.
47.98+47.98